EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Third Harmonic Bio's enterprise value is $-34.85 Mil.
Third Harmonic Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-66.25 Mil. Therefore, Third Harmonic Bio's EV-to-EBITDA for today is 0.53.
The historical rank and industry rank for Third Harmonic Bio's EV-to-EBITDA or its related term are showing as below:
THRD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.53
Current: 0.53
During the past 5 years, the highest EV-to-EBITDA of Third Harmonic Bio was 0.53. The lowest was 0.00. And the median was 0.00.
THRD's EV-to-EBITDA is ranked better than 76.45% of 501
companies
in the Biotechnology industry
Industry Median: 7.89
vs THRD: 0.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Third Harmonic Bio EV-to-EBITDA Historical Data
The historical data trend for Third Harmonic Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Third Harmonic Bio's EV-to-EBITDA
For the Biotechnology subindustry, Third Harmonic Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Third Harmonic Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Third Harmonic Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Third Harmonic Bio's EV-to-EBITDA falls into.
Third Harmonic Bio's current Enterprise Value is $-34.85 Mil.
Third Harmonic Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Third Harmonic Bio (NAS:THRD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Third Harmonic Bio's PE Ratio (TTM) for today is calculated as:
Third Harmonic Bio's share price for today is $5.20.
Third Harmonic Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Third Harmonic Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
THRD has been successfully added to your 